1783 Stock Overview
Maxigen Biotech Inc. researches, develops, produces, and sells implantable medical device and cosmetic products in Taiwan, the United States, Europe, rest of Asia, and internationally.
Maxigen Biotech Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||NT$40.55|
|52 Week High||NT$61.60|
|52 Week Low||NT$34.20|
|1 Month Change||-17.92%|
|3 Month Change||-6.13%|
|1 Year Change||-19.06%|
|3 Year Change||63.51%|
|5 Year Change||70.74%|
|Change since IPO||-19.38%|
Recent News & Updates
|1783||TW Personal Products||TW Market|
Return vs Industry: 1783 underperformed the TW Personal Products industry which returned -6.2% over the past year.
Return vs Market: 1783 matched the TW Market which returned -19.3% over the past year.
|1783 Average Weekly Movement||7.5%|
|Personal Products Industry Average Movement||5.9%|
|Market Average Movement||5.2%|
|10% most volatile stocks in TW Market||8.4%|
|10% least volatile stocks in TW Market||2.5%|
Stable Share Price: 1783 is more volatile than 75% of TW stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: 1783's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
Maxigen Biotech Inc. researches, develops, produces, and sells implantable medical device and cosmetic products in Taiwan, the United States, Europe, rest of Asia, and internationally. It operates in two segments, Biomedical Products and Consumer Products. The company offers intra-articular injections under the ArtiAid, ArtiAid Plus, and ArtiBest names to treat osteoarthritis; Foramic, a bone substitute granule; FormaGraft, a bone graft substitute; GingivAid, a collagen dental grafts for use in dental implant surgery; BestAid, a collagen bone graft; FormaSetin, an injectable bone void filler; and MaxiBone, a calcium phosphate ceramic.
Maxigen Biotech Fundamentals Summary
|1783 fundamental statistics|
Is 1783 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|1783 income statement (TTM)|
|Cost of Revenue||NT$263.35m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||1.28|
|Net Profit Margin||17.71%|
How did 1783 perform over the long term?See historical performance and comparison
1.8%Current Dividend Yield
Is 1783 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 1783?
Other financial metrics that can be useful for relative valuation.
|What is 1783's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does 1783's PE Ratio compare to its peers?
|1783 PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
8480 Taisun Int'l (Holding)
6523 Dr. Wu Skincare
6703 Shiny Brands Group
1783 Maxigen Biotech
Price-To-Earnings vs Peers: 1783 is expensive based on its Price-To-Earnings Ratio (31.6x) compared to the peer average (14.7x).
Price to Earnings Ratio vs Industry
How does 1783's PE Ratio compare vs other companies in the Asian Personal Products Industry?
Price-To-Earnings vs Industry: 1783 is expensive based on its Price-To-Earnings Ratio (31.6x) compared to the Asian Personal Products industry average (25.6x)
Price to Earnings Ratio vs Fair Ratio
What is 1783's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||31.6x|
|Fair PE Ratio||n/a|
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 1783's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of 1783 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 1783 (NT$40.55) is trading below our estimate of fair value (NT$127.84)
Significantly Below Fair Value: 1783 is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Maxigen Biotech forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Household industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Maxigen Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Check out Maxigen Biotech's track record over time to understand how much the company has returned to shareholders and its earnings growth rate in the past.
How has Maxigen Biotech performed over the past 5 years?
Past Performance Score5/6
Past Performance Score 5/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 1783 has high quality earnings.
Growing Profit Margin: 1783's current net profit margins (17.7%) are higher than last year (16.1%).
Past Earnings Growth Analysis
Earnings Trend: 1783's earnings have grown significantly by 26.3% per year over the past 5 years.
Accelerating Growth: 1783's earnings growth over the past year (30.5%) exceeds its 5-year average (26.3% per year).
Earnings vs Industry: 1783 earnings growth over the past year (30.5%) exceeded the Personal Products industry -11.6%.
Return on Equity
High ROE: 1783's Return on Equity (8.2%) is considered low.
Discover strong past performing companies
How is Maxigen Biotech's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: 1783's short term assets (NT$863.4M) exceed its short term liabilities (NT$113.7M).
Long Term Liabilities: 1783's short term assets (NT$863.4M) exceed its long term liabilities (NT$20.0K).
Debt to Equity History and Analysis
Debt Level: 1783 is debt free.
Reducing Debt: 1783 has no debt compared to 5 years ago when its debt to equity ratio was 28.8%.
Debt Coverage: 1783 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 1783 has no debt, therefore coverage of interest payments is not a concern.
Discover healthy companies
What is Maxigen Biotech current dividend yield, its reliability and sustainability?
Dividend Score 2/6
Cash Flow Coverage
Current Dividend Yield
Dividend Yield vs Market
|Maxigen Biotech Dividend Yield vs Market|
|Company (Maxigen Biotech)||1.8%|
|Market Bottom 25% (TW)||2.6%|
|Market Top 25% (TW)||7.0%|
|Industry Average (Personal Products)||3.8%|
|Analyst forecast in 3 Years (Maxigen Biotech)||n/a|
Notable Dividend: 1783's dividend (1.8%) isn’t notable compared to the bottom 25% of dividend payers in the TW market (2.57%).
High Dividend: 1783's dividend (1.8%) is low compared to the top 25% of dividend payers in the TW market (7.03%).
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, 1783 has been paying a dividend for less than 10 years.
Growing Dividend: 1783's dividend payments have increased, but the company has only paid a dividend for 5 years.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonable payout ratio (56.4%), 1783's dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonably low cash payout ratio (30.8%), 1783's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Ms. Ching-Ting Chen serves as Head of Research & Design Center at TCI Co., Ltd. since February 5, 2020. She served as R&D chief, TCI Co., Ltd.She holds Master’s Degree in Chemistry, National Taiwan Univer...
Experienced Board: 1783's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Maxigen Biotech Inc.'s employee growth, exchange listings and data sources
- Name: Maxigen Biotech Inc.
- Ticker: 1783
- Exchange: TWSE
- Founded: 1998
- Industry: Personal Products
- Sector: Household
- Implied Market Cap: NT$3.142b
- Shares outstanding: 77.00m
- Website: https://mbi-bio.com
- Maxigen Biotech Inc.
- No. 88, Keji 1st Road
- Guishan District
- Taoyuan City
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|1783||TWSE (Taiwan Stock Exchange)||Yes||Common Stock||TW||TWD||May 2011|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/30 00:00|
|End of Day Share Price||2022/09/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.